Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587237 | 0.97 | CYP1A2 (0.50) | CYP1A2CHRM5ADRA2CHRH3ALDH1A1 | |
| SCHEMBL12945 | 0.92 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL3218288 | 0.92 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL30340999 | 0.92 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL10949210 | 0.90 | CHRM5 (0.54) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL7166922 | 0.87 | CYP1A2 (0.44) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL12038519 | 0.86 | CYP1A2 (0.52) | CYP1A2CHRM5ADRA2CHRH3CARM1 | |
| SCHEMBL14686114 | 0.86 | DRD2 (0.48) | CYP1A2CHRM5ADRA2CHRH3MAPT | |
| SCHEMBL14081462 | 0.86 | CYP1A2 (0.52) | CYP1A2CHRM5ADRA2CHRH3CARM1 | |
| SCHEMBL14686115 | 0.86 | DRD2 (0.48) | CYP1A2CHRM5ADRA2CHRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017011214-A1 | SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017008205-A1 | SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-8101550-B2 | Anthranilic acid diamide derivative with hetero-aromatic and hetero-cyclic substituents | BAYER CROPSCIENCE AG (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20100029478-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| WO-2007144100-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS | BAYER CROPSCIENCE AG (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029478-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS | DDT, ANTXR2, QDPR | CYP1A2 64/4885CHRM5 420/4885ADRA2C 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.